[Up to date lipid lowering treatment].

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipidology

Background:

• The "lower the better" approach for lowering LDL cholesterol is established for cardiovascular risk reduction.
• Statin therapy significantly reduces cardiovascular events but leaves residual risk, particularly in severe hereditary hypercholesterolemia like familial hypercholesterolemia.

Purpose of the Study:

• To summarize the efficacy and clinical indications of novel agents for achieving lower LDL cholesterol levels.
• To review current guidelines for managing hypercholesterolemia with new therapeutic options.

Main Methods:

• Review of existing evidence on new LDL-lowering agents.
• Analysis of clinical indications and efficacy data for ezetimibe and PCSK9 monoclonal antibodies.
• Examination of current treatment guidelines.

Main Results:

• New strategies, including cholesterol absorption inhibitors (ezetimibe) and PCSK9 monoclonal antibodies, can achieve lower LDL cholesterol levels.
• These agents are effective alternatives for patients intolerant to statins.
• Significant residual cardiovascular risk can be further mitigated with these novel therapies.

Conclusions:

• Novel LDL-lowering therapies provide valuable options for managing hypercholesterolemia, especially in high-risk populations.
• These agents expand treatment possibilities for patients with familial hypercholesterolemia and those unable to tolerate statins.
• Current guidelines support the use of these new agents to further reduce cardiovascular risk.